As mentioned earlier, HIF-1 plays a significant role in HCC chemotherapy resistance and thereby limits the efficiency of sorafenib, which is the only approved targeted small molecular drug for HCC therapy. Here, HIF1A is linked to hepatocellular carcinoma.